Expanding the Role of Suprachoroidal Injections - Poll - MDSpire

Expanding the Role of Suprachoroidal Injections

Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.

  • By

  • Thomas A. Ciulla, MD, MBA

  • September 1, 2025

  • 18 min

Share

Original Source(s)

Expanding the Role of Suprachoroidal Injections

  • by Thomas A. Ciulla, MD, MBA

  • September 1, 2025

Related Content

Clinical Trial Update July/August 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

  • July 1, 2026

  • 46 min
Ocular Toxoplasmosis Review

Sleep, stress, and pregnancy emerge as potential drivers of ocular toxoplasmosis recurrence in recent retrospective study

  • July 15, 2026

  • 4 min
GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.